Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT00196742
Other study ID # DIREGC07006
Secondary ID AGAL19211U1111-1
Status Recruiting
Phase
First received
Last updated
Start date July 31, 2001
Est. completion date January 31, 2034

Study information

Verified date April 2024
Source Sanofi
Contact Trial Transparency
Phone 800-633-1610
Email Contact-Us@sanofi.com
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

The Fabry Registry is an ongoing, international multi-center, strictly observational program that tracks the routine clinical outcomes for patients with Fabry disease, irrespective of treatment status. No experimental intervention is involved; patients in the Registry undergo clinical assessments and receive care as determined by the patient's treating physician. The primary objectives of the Registry are: - To enhance the understanding of the variability, progression, and natural history of Fabry disease, including heterozygous females with the disease; - To assist the Fabry medical community with the development of recommendations for monitoring patients and reports on patient outcomes to help optimize patient care; - To characterize and describe the Fabry population as a whole; - To evaluate the long-term safety and effectiveness of Fabrazyme® Fabry Pregnancy Sub-registry: This Sub-registry is a multicenter, international, longitudinal, observational, and voluntary program designed to track pregnancy outcomes for any pregnant woman enrolled in the Fabry Registry, regardless of whether she is receiving disease-specific therapy (such as enzyme replacement therapy with agalsidase beta) and irrespective of the commercial product with which she may be treated. Data from the Sub-registry are also used to fulfill various global regulatory requirements, to support product development/reimbursement, and for other research and non-research-related purposes. No experimental intervention is given; thus a patient will undergo clinical assessments and receive standard of care treatment as determined by the patient's physician. If a patient consents to this Sub-registry, information about the patient's medical and obstetric history, pregnancy, and birth will be collected, and, if a patient consents to data collection for her infant, data on infant growth through month 36 postpartum will be collected.


Recruitment information / eligibility

Status Recruiting
Enrollment 9000
Est. completion date January 31, 2034
Est. primary completion date January 31, 2034
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria - Fabry Registry: All patients with a confirmed diagnosis of Fabry disease who have signed the informed consent and patient authorization form(s) are eligible for inclusion. Confirmed diagnosis is defined as a documented deficiency in plasma or leukocyte aGAL (alpha-galactosidase) enzyme activity and/or mutation(s) in the gene coding for aGAL. - Fabry Pregnancy Sub-registry: - Eligible women must: - be enrolled in the Fabry Registry. - be pregnant, or have been pregnant with appropriate medical documentation available. - provide a signed informed consent and authorization form(s) to participate in the Sub-Registry prior to any Sub-Registry-related data collection being performed. Exclusion Criteria Fabry Registry: There are no exclusion criteria. Fabry Pregnancy Sub-registry: There are no exclusion criteria.

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
Argentina Investigational Site Number : 153130 Buenos Aires
Argentina Investigational Site Number : 153172 Caba Buenos Aires
Argentina Investigational Site Number : 153194 Catamarca
Argentina Investigational Site Number : 153032 Ciudad Autónoma de Buenos Aires Buenos Aires
Argentina Investigational Site Number : 032005 La Rioja
Argentina Investigational Site Number : 032004 Santa Fe
Australia Investigational Site Number : 151002 Adelaide South Australia
Australia Investigational Site Number : 153063 Herston Queensland
Australia Investigational Site Number : 153040 Parkville Victoria
Australia Investigational Site Number : 153090 Perth Western Australia
Australia Investigational Site Number : 036013 Westmead New South Wales
Australia Investigational Site Number : 151069 Westmead New South Wales
Belgium Investigational Site Number : 150722 Antwerpen
Belgium Investigational Site Number : 153133 Antwerpen
Belgium Investigational Site Number : 153001 Brussels
Belgium Investigational Site Number : 150517 Bruxelles
Belgium Investigational Site Number : 0560008 Jette
Belgium Investigational Site Number : 151668 Leuven
Belgium Investigational Site Number : 154275 Liège
Belgium Investigational Site Number : 153100 Seraing
Brazil Medicordis Site Number : 076009 Brasília Distrito Federal
Brazil PUC Campinas - Sociedade Campineira de Educaçao e Instruçao Site Number : 076013 Campinas São Paulo
Brazil Hospital Geral e Maternidade de Cuiabá Site Number : 076006 Cuiabá Mato Grosso
Brazil Instituto do Rim do Paraná Site Number : 076004 Curitiba Paraná
Brazil Clínica Senhor do Bonfim LTDA Site Number : 076008 Feira de Santana Bahia
Brazil Hospital Universitário Professor Polydoro Ernani de São Thiago - UFSC Site Number : 076012 Florianopolis Santa Catarina
Brazil Serviço de Terapia Renal de Ourinhos Site Number : 076011 Ourinhos São Paulo
Brazil Instituto de Medicina Integral Professor Fernando Figueira - IMIP Site Number : 076005 Recife Pernambuco
Brazil Instituto de Genética e Erros Inatos do Metabolismo - IGEIM Site Number : 076001 São Paulo
Brazil Saúde Center Clínica - Clínica Médica Nossa Senhora de Fátima Site Number : 076002 Tapejara Rio Grande Do Sul
Brazil CTDR - Centro de Tratamento de Doenças Renais EIRELI Site Number : 076007 Uberlândia Minas Gerais
Bulgaria Investigational Site Number : 100001 Sofia
Bulgaria Investigational Site Number : 153169 Sofia
Canada Investigational Site Number : 124014 Calgary Alberta
Canada Investigational Site Number : 124002 Edmonton Alberta
Canada Investigational Site Number : 124008 Halifax Nova Scotia
Canada Investigational Site Number : 124021 London Ontario
Canada Investigational Site Number : 124022 Moncton New Brunswick
Canada Investigational Site Number : 124013 Montreal Quebec
Canada Investigational Site Number : 124001 Sherbrooke Quebec
Canada Investigational Site Number : 124023 St. John's Newfoundland and Labrador
Canada Investigational Site Number : 124006 Toronto Ontario
Canada Investigational Site Number : 124009 Toronto Ontario
Canada Investigational Site Number : 124010 Vancouver British Columbia
Canada Investigational Site Number : 124011 Vancouver British Columbia
Canada Investigational Site Number : 124019 Winnipeg Manitoba
Chile Investigational Site Number : 152004 Antofagasta
Chile Investigational Site Number : 152001 Coquimbo
Chile Investigational Site Number : 152003 Iquique
Chile Investigational Site Number : 152005 Vallenar
China Investigational Site Number : 1560003 Hangzhou
China Investigational Site Number : 1560002 Jinan
China Investigational Site Number : 1560004 Nanjing
Colombia Investigational Site Number : 170001 Bogotá
Croatia Investigational Site Number : 1910001 Rijena
Croatia Investigational Site Number : 1910002 Zagreb
Czechia Investigational Site Number : 153126 Praha 2
Denmark Investigational Site Number : 153041 Copenhagen
Denmark Investigational Site Number : 151229 København Ø
Estonia Investigational Site Number : 153106 Tartu
Finland Investigational Site Number : 153024 Turku
France Investigational Site Number : 250005 Bordeaux
France Investigational Site Number : 250002 BRON Cedex
France Investigational Site Number : 250001 Garches
France Investigational Site Number : 250007 Lille
France Investigational Site Number : 250003 LIMOGES Cedex
France Investigational Site Number : 250006 Marseille
France Investigational Site Number : 250004 Saint Priest en Jarez
France Investigational Site Number : 250009 Strasbourg
Germany Investigational Site Number : 153013 Berlin
Germany Investigational Site Number : 154150 Gießen
Germany Investigational Site Number : 153147 Münster
Germany Investigational Site Number : 153011 Würzburg
Hong Kong Investigational Site Number : 344001 Kowloon
Hungary Investigational Site Number : 3480002 Budapest
Hungary Investigational Site Number : 3480003 Létavértes
Hungary Investigational Site Number : 3480005 Pécs
Hungary Investigational Site Number : 3480004 Sopron
India Investigational Site Number : 356003 Ahmedabad
India Investigational Site Number : 356001 Kolkata
India Investigational Site Number : 3560004 Secunderabad
India Investigational Site Number : 356002 Vellore
Indonesia Investigational Site Number : 360001 Jakarta
Italy Investigational Site Number : 380002 Bassano Del Grappa (VI)
Italy Investigational Site Number : 380004 Firenze
Italy Investigational Site Number : 380013 Firenze
Italy Investigational Site Number : 380005 Genova
Italy Investigational Site Number : 380006 Milano
Italy Investigational Site Number : 380009 Milano
Italy Investigational Site Number : 380003 Modena
Italy Investigational Site Number : 380010 Monza (MB)
Italy Investigational Site Number : 380008 Napoli
Italy Investigational Site Number : 380007 Rimini
Italy Investigational Site Number : 380012 Roma
Italy Investigational Site Number : 380011 Torino
Italy Investigational Site Number : 380001 Udine
Italy Investigational Site Number : 380014 Vittoria (RG)
Japan Investigational Site Number : 153205 Abeno-ku Osaka
Japan Investigational Site Number : 153217 Chiba
Japan Investigational Site Number : 392007 Kobe-shi, Hyogo
Japan Investigational Site Number : 153201 Nangoku-shi Kochi
Japan Investigational Site Number : 392006 Niigata-shi Niigata
Japan Investigational Site Number : 153204 Setagaya Tokyo
Korea, Republic of Investigational Site Number : 154246 Busan
Korea, Republic of Investigational Site Number : 153191 Daejeon
Korea, Republic of Investigational Site Number : 153225 Jeonnam
Korea, Republic of Investigational Site Number : 151149 Seoul
Korea, Republic of Investigational Site Number : 153180 Seoul
Korea, Republic of Investigational Site Number : 153188 Seoul
Korea, Republic of Investigational Site Number : 153192 Seoul
Korea, Republic of Investigational Site Number : 153196 Seoul
Korea, Republic of Investigational Site Number : 153212 Seoul
Korea, Republic of Investigational Site Number : 153222 Seoul
Korea, Republic of Investigational Site Number : 154273 Suwon-si
Korea, Republic of Investigational Site Number : 154148 Yangsan Gyeongsangnam-do
Korea, Republic of Investigational Site Number : 153178 Yangsan-si Gyeongsangnam-do
Kuwait Investigational Site Number : 154225 Kuwait
Lithuania Investigational Site Number : 154244 Vilnius
Lithuania Investigational Site Number : 154652 Vilnius
Malaysia Investigational Site Number : 458001 Jalan Pahang
Malaysia Investigational Site Number : 458002 Kuala Lumpur
Norway Investigational Site Number : 153141 Bergen
Peru Investigational Site Number : 604002 Callao
Philippines Investigational Site Number : 608001 Manila
Poland Investigational Site Number : 150575 Warszawa
Portugal Investigational Site Number : 620005 Lisboa
Portugal Investigational Site Number : 620001 Porto
Romania Investigational Site Number : 154099 Bucuresti
Romania Investigational Site Number : 154164 Bucuresti
Romania Investigational Site Number : 153081 Cluj-Napoca
Russian Federation Investigational Site Number : 643001 Moscow
Russian Federation Investigational Site Number : 643003 Nizhny Novgorod
Russian Federation Investigational Site Number : 643002 Saint-Peterburg
Saudi Arabia Investigational Site Number : 682002 Al Mubarraz
Serbia Investigational Site Number : 6880001 Novi Sad
Singapore Investigational Site Number : 702001 Singapore
Slovakia Investigational Site Number : 703001 Bratislava
Slovenia Investigational Site Number : 705001 Slovenj Gradec
Spain Investigational Site Number : 154135 Barakaldo
Spain Investigational Site Number : 153067 Barcelona
Spain Investigational Site Number : 153077 Barcelona
Spain Investigational Site Number : 153237 Barcelona
Spain Investigational Site Number : 154123 Barcelona
Spain Investigational Site Number : 154147 Barcelona
Spain Investigational Site Number : 154204 Barcelona
Spain Investigational Site Number : 154146 La Coruña
Spain Investigational Site Number : 154159 La Coruña
Spain Investigational Site Number : 154136 Tarragona
Spain Investigational Site Number : 153213 Vigo
Sweden Investigational Site Number : 153050 Göteborg
Sweden Investigational Site Number : 151484 Stockholm
Taiwan Investigational Site Number : 154093 Chiayi
Taiwan Investigational Site Number : 152152 Hualien
Taiwan Investigational Site Number : 152244 Kaohsiung
Taiwan Investigational Site Number : 153088 Kaohsiung City
Taiwan Investigational Site Number : 152246 Kaohsiung Hsien,
Taiwan Investigational Site Number : 151534 New Taipei City
Taiwan Investigational Site Number : 151500 Putz City, Chia-yi
Taiwan Investigational Site Number : 151181 Taichung
Taiwan Investigational Site Number : 151179 Taichung City
Taiwan Investigational Site Number : 152153 Tainan
Taiwan Investigational Site Number : 153248 Tainan
Taiwan Investigational Site Number : 151182 Taipei
Taiwan Investigational Site Number : 152226 Taipei
Taiwan Investigational Site Number : 152321 Taipei
Taiwan Investigational Site Number : 153158 Tao Yuan County
Thailand Investigational Site Number : 764001 Bangkok
Thailand Investigational Site Number : 764003 Bangkok
Thailand Investigational Site Number : 764004 Bangkok
Thailand Investigational Site Number : 764005 Khon Kaen
United Kingdom Investigational Site Number : 154196 Belfast
United Kingdom Investigational Site Number : 152287 Birmingham
United Kingdom Investigational Site Number : 151340 Cambridge Cambridgeshire
United Kingdom Investigational Site Number : 150303 London
United Kingdom Investigational Site Number : 151123 London
United Kingdom Investigational Site Number : 151646 London
United Kingdom Investigational Site Number : 150455 Manchester
United Kingdom Investigational Site Number : 152361 Salford
United States University of Michigan Pediatrics Site Number : 840107 Ann Arbor Michigan
United States John Hopkins Site Number : 840044 Baltimore Maryland
United States Ochsner Medical Center Site Number : 840120 Baton Rouge Louisiana
United States Billings Clinic Site Number : 840118 Billings Montana
United States University of Alabama Birmingham- Nephrology Site Number : 840018 Birmingham Alabama
United States University of Alabama Birmingham- Nephrology Site Number : 840073 Birmingham Alabama
United States Boston Children's Hospital Site Number : 840092 Boston Massachusetts
United States Brigham and Women's Hospital-Neurology Site Number : 840103 Boston Massachusetts
United States Massachusetts General Hospital-Genetics Site Number : 840062 Boston Massachusetts
United States Carolinas Medical Center Site Number : 840065 Charlotte North Carolina
United States University of Virginia School of Medicine-Pediatrics Site Number : 840078 Charlottesville Virginia
United States Ann and Robert Lurie Children's Hospital Site Number : 840013 Chicago Illinois
United States Rush University Medical Center Genetics Site Number : 840079 Chicago Illinois
United States Cincinnati Children's Hospital-Genetics Site Number : 840033 Cincinnati Ohio
United States Cleveland Clinic Foundation Pediatrics Site Number : 840048 Cleveland Ohio
United States UHCMC Site Number : 840119 Cleveland Ohio
United States Nationwide Children's Hospital Site Number : 840091 Columbus Ohio
United States Ohio State University Department of Genetics Site Number : 840097 Columbus Ohio
United States University of Missouri Health System Department of Genetics Site Number : 840031 Columibia Missouri
United States University Hematology Oncology Site Number : 840075 Coral Springs Florida
United States Baylor Research Center Site Number : 840058 Dallas Texas
United States Geisinger Site Number : 840111 Danville Pennsylvania
United States Emory University School of Medicine- Human Genetics Site Number : 840060 Decatur Georgia
United States University of Colorado at Denver Genetics Site Number : 840068 Denver Colorado
United States Children's Hospital of Michigan Site Number : 840066 Detroit Michigan
United States LSD Data Registry Site LLC Site Number : 840094 Dublin Ohio
United States Duke University Medical Center Genetics Dept Site Number : 840045 Durham North Carolina
United States O&O Alpan, LLC Site Number : 840025 Fairfax Virginia
United States Cook Children's Health Care System Site Number : 840024 Fort Worth Texas
United States University of Florida Dept of Genetics Site Number : 840083 Gainesville Florida
United States Infusion Associates Site Number : 840050 Grand Rapids Michigan
United States Spectrum for Health Site Number : 840019 Grand Rapids Michigan
United States Greenwood Genetcs Site Number : 840055 Greenville South Carolina
United States Joseph M. Sanzari Children's Hospital Site Number : 840101 Hackensack New Jersey
United States Shodair Children's Hospital Site Number : 840090 Helena Montana
United States Penn State University Medical Center-Neurology Site Number : 840104 Hershey Pennsylvania
United States Indianapolis University School of Medicine Site Number : 840027 Indianapolis Indiana
United States University of Iowa Site Number : 840032 Iowa City Iowa
United States University of California at Irvine Site Number : 840036 Irvine California
United States The Atwal Clinic Site Number : 840112 Jacksonville Florida
United States University of Florida Pediatrics Genetics Site Number : 840121 Jacksonville Florida
United States University Of Kansas Medical Center Site Number : 840071 Kansas City Kansas
United States Children's Specialty Center of Nevada Site Number : 840008 Las Vegas Nevada
United States Arkansas Childrens Hospital Site Number : 840109 Little Rock Arkansas
United States University of Arkansas for Medical Sciences Site Number : 840113 Little Rock Arkansas
United States Southern California Permanente Medical Group Site Number : 840108 Los Angeles California
United States UCLA School Of Medicine Site Number : 840088 Los Angeles California
United States USC Health Sciences Center Dept of Genetics Site Number : 840082 Los Angeles California
United States University of Louisville- Genetics Site Number : 840030 Louisville Kentucky
United States Northwell Health Site Number : 840102 Manhasset New York
United States University Of Miami SOM Site Number : 840006 Miami Florida
United States Children's Hospital of Wisconsin-Pediatrics Site Number : 840054 Milwaukee Wisconsin
United States Children's Health Care Site Number : 840114 Minneapolis Minnesota
United States Children's Hospital and Clinics of Minnesota Site Number : 840046 Minneapolis Minnesota
United States University of Minnesota Medical Center Pediatrics Site Number : 840076 Minneapolis Minnesota
United States Atlantic Health System Site Number : 840099 Morristown New Jersey
United States Vanderbilt University Hospital-Pediatrics Site Number : 840049 Nashville Tennessee
United States St. Peter's University Hospital Site Number : 840016 New Brunswick New Jersey
United States Yale Site Number : 840047 New Haven Connecticut
United States Tulane University Medical Center Site Number : 840001 New Orleans Louisiana
United States Icahn School of Medicine Site Number : 840080 New York New York
United States Metropolitan Hospital Center Site Number : 840110 New York New York
United States New York University School Of Medicine Site Number : 840040 New York New York
United States Children's Hospital of the Kings Daughters Site Number : 840072 Norfolk Virginia
United States Children's Hospital Oakland Site Number : 840029 Oakland California
United States University of Nebraska Medical Center- Pediatrics Site Number : 840084 Omaha Nebraska
United States Children's Hospital of Orange County Site Number : 840074 Orange California
United States Stanford Unviersity MC Dept of Genetics Site Number : 840022 Palo Alto California
United States St. Joseph's Children's Hospital Site Number : 840057 Paterson New Jersey
United States Children's Hospital of Philadelphia HUP Medical Genetics Site Number : 840089 Philadelphia Pennsylvania
United States Children's Hospital of Philadelphia Site Number : 840034 Philadelphia Pennsylvania
United States Phoenix Children's Hospital Site Number : 840003 Phoenix Arizona
United States University of Pittsburgh Site Number : 840023 Pittsburgh Pennsylvania
United States Maine Medical Center Pediatrics Site Number : 840064 Portland Maine
United States Oregon Health & Science University Site Number : 840116 Portland Oregon
United States Rhode Island Hospital Genetics Site Number : 840053 Providence Rhode Island
United States University of Rochester Medical Center SOM Site Number : 840105 Rochester New York
United States Kaiser Permanente Hospital Site Number : 840042 Sacramento California
United States UC Davis MIND Institute Site Number : 840010 Sacramento California
United States Washington University of St. Louis Site Number : 840100 Saint Louis Missouri
United States University of Utah Department of Medical Genetics Site Number : 840043 Salt Lake City Utah
United States Loma Linda University Children's Hospital Site Number : 840117 San Bernardino California
United States University of California at San Diego Site Number : 840007 San Diego California
United States University of California at San Francisco Site Number : 840051 San Francisco California
United States Seattle Children's Hospital Site Number : 840028 Seattle Washington
United States University Of Washington Medical Center Site Number : 840059 Seattle Washington
United States Baystate Health Site Number : 840002 Springfield Massachusetts
United States State University of New York Site Number : 840052 Syracuse New York
United States Multicare Health System ¿ Mary Bridge Childrens Hospital Site Number : 840115 Tacoma Washington
United States University of Florida-Genetics Site Number : 840096 Tampa Florida
United States University of Arizona Site Number : 840015 Tucson Arizona
United States New York Medical College Site Number : 840039 Valhalla New York
United States Children's National Medical Center Site Number : 840067 Washington District of Columbia
Vietnam Investigational Site Number : 154212 Hanoi

Sponsors (1)

Lead Sponsor Collaborator
Genzyme, a Sanofi Company

Countries where clinical trial is conducted

United States,  Vietnam,  Argentina,  Australia,  Belgium,  Brazil,  Bulgaria,  Canada,  Chile,  China,  Colombia,  Croatia,  Czechia,  Denmark,  Estonia,  Finland,  France,  Germany,  Hong Kong,  Hungary,  India,  Indonesia,  Italy,  Japan,  Korea, Republic of,  Kuwait,  Lithuania,  Malaysia,  Norway,  Peru,  Philippines,  Poland,  Portugal,  Romania,  Russian Federation,  Saudi Arabia,  Serbia,  Singapore,  Slovakia,  Slovenia,  Spain,  Sweden,  Taiwan,  Thailand,  United Kingdom, 

References & Publications (3)

Germain DP, Brand E, Burlina A, Cecchi F, Garman SC, Kempf J, Laney DA, Linhart A, Marodi L, Nicholls K, Ortiz A, Pieruzzi F, Shankar SP, Waldek S, Wanner C, Jovanovic A. Phenotypic characteristics of the p.Asn215Ser (p.N215S) GLA mutation in male and female patients with Fabry disease: A multicenter Fabry Registry study. Mol Genet Genomic Med. 2018 Apr 12;6(4):492-503. doi: 10.1002/mgg3.389. Online ahead of print. — View Citation

Hopkin RJ, Cabrera G, Charrow J, Lemay R, Martins AM, Mauer M, Ortiz A, Patel MR, Sims K, Waldek S, Warnock DG, Wilcox WR. Risk factors for severe clinical events in male and female patients with Fabry disease treated with agalsidase beta enzyme replacement therapy: Data from the Fabry Registry. Mol Genet Metab. 2016 Sep;119(1-2):151-9. doi: 10.1016/j.ymgme.2016.06.007. Epub 2016 Jun 13. — View Citation

Wilcox WR, Feldt-Rasmussen U, Martins AM, Ortiz A, Lemay RM, Jovanovic A, Germain DP, Varas C, Nicholls K, Weidemann F, Hopkin RJ. Improvement of Fabry Disease-Related Gastrointestinal Symptoms in a Significant Proportion of Female Patients Treated with Agalsidase Beta: Data from the Fabry Registry. JIMD Rep. 2018;38:45-51. doi: 10.1007/8904_2017_28. Epub 2017 May 17. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Fabry Registry: To evaluate the long-term safety and effectiveness of Fabrazyme® The primary purpose of this Registry is to describe the development and progression of Fabry disease in a representative global population. As Fabry is not a well-described disease this longitudinal program has a wide variety of "primary" outcomes including antibody testing as well as complication outcomes (eg, QoL, cognitive testing) which are measured over time. Additionally, as it is subject to what is collected by clinical sites at the time of visit it is unknown the amount of data that will be available for analyses. 33 years
Primary Fabry Pregnancy Sub-registry: pregnancy outcomes, including complications and infant growth The primary objective of this Sub-registry is to track pregnancy outcomes, including complications and infant growth, in all women with Fabry disease during pregnancy, regardless of whether they receive disease-specific therapy, such as ERT with agalsidase beta.
This Sub-registry augments the routine monitoring and data collection recommended by the Fabry Registry. The Sub-registry aims to collect patient assessments from the ante- and perinatal periods and postpartum follow-up. Neonatal assessments and periodic pediatric assessments will also be collected.
33 years
Secondary Fabry Register: Monitor factors associated with the efficacy of Fabry disease treatments A secondary endpoint is to monitor those factors associated with the efficacy of Fabry disease treatments. 33 years
See also
  Status Clinical Trial Phase
Recruiting NCT04893889 - Substudy (NCT04456582): Noninvasive Assessment of Myocardial Stiffness by 2D-SWE Ultrasound Technique (Two-dimensional Shear Wave Elastography) in Patients With Amyloidosis and Fabry Disease. N/A
Completed NCT04455230 - A Long Term Follow-Up Study of Fabry Disease Subjects Treated With FLT190 Phase 1/Phase 2
Completed NCT01218659 - Study to Compare the Efficacy and Safety of Oral AT1001 and Enzyme Replacement Therapy in Patients With Fabry Disease Phase 3
Completed NCT00304512 - A 12-Week Safety and Pharmacodynamic Study of AT1001 (Migalastat Hydrochloride) in Female Participants With Fabry Disease Phase 2
Withdrawn NCT04189601 - Complement Activation in the Lysosomal Storage Disorders
Completed NCT03500094 - Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged 12 to <18 Years) Phase 3
Withdrawn NCT04143958 - To Assess the Glycosphingolipid Clearance and Clinical Effects of Switching to Agalsidase Beta (Fabrazyme) Versus Continuing on Agalsidase Alfa (Replagal) in Male Patients With Classic Fabry Disease Phase 4
Recruiting NCT02994303 - Podocyturia - Predictor of Renal Dysfunction in Fabry Nephropathy N/A
Completed NCT01947634 - Sleepiness and Sleep-disordered Breathing in Fabry Disease. A Prospective Cohort Study. N/A
Recruiting NCT01695161 - Non-invasive Assessment of Intraocular Pressure in MPS by Use of the Ocular Response Analyzer. N/A
Completed NCT01853852 - A Phase I, Randomized, Single-Blind, Four-Period Cross-Over, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety and Pharmacokinetics of Single Oral Doses of GR181413A/AT1001 in Healthy Japanese Subjects Phase 1
Completed NCT00701415 - A Study of Two Fabrazyme (Agalsidase Beta) Dosing Regimens in Treatment-naïve, Male Pediatric Patients Without Severe Symptoms Phase 3
Completed NCT00068107 - Dosing Study of Replagal in Patients With Fabry Disease Phase 2
Completed NCT01997489 - Ophthalmic Findings During 10-year Enzyme Substitution of Danish Fabry Patients. Phase 4
Recruiting NCT06007768 - Autoimmune and Inflammatory Response Biomarkers in Fabry Disease
Recruiting NCT05698901 - Biomarkers and Cardiac Imaging Diagnostic Assay for Monitoring Patients With Fabry Disease
Active, not recruiting NCT03305250 - Arrhythmia Burden, Risk of Sudden Cardiac Death and Stroke in Patients With Fabry Disease N/A
Terminated NCT00526071 - Open-label Long-term Safety Study of AT1001 (Migalastat Hydrochloride) in Participants With Fabry Disease Who Have Completed a Previous AT1001 Study Phase 2
Active, not recruiting NCT03566017 - Open Label Extension Study of 1 mg/kg Pegunigalsidase Alfa Every 2 Weeks in Patients With Fabry Disease Phase 3
Recruiting NCT06065605 - Assess Urine Biomarkers to Predict Nephropathy in Fabry Disease